Skip to main content

Gene Therapy as a Novel Pharmaceutical Intervention for Stroke

Buy Article:

$68.00 + tax (Refund Policy)

Cerebrovascular disease is the leading cause of death and disability in Japan and most Western countries. Gene transfer techniques may be applicable to the treatment of serious types of stroke, since several experimental studies have revealed the usefulness of gene therapy in the protection of neurons, reduction of infarct size and improvement of function. Prevention of vasospasm after subarachnoid hemorrhage is one of the best candidates for vascular gene therapy. Ischemia-induced apoptosis, inflammation, and derangement of neurovascular units can be targeted by the gene transfer approach. Recent studies have shown that promotion of neurogenesis and functional recovery may also be achieved by this strategy. Furthermore, a combination of stem cell therapy with gene transfer methods may be feasible. This review describes novel approaches for the treatment of stroke using gene transfer techniques.





Keywords: Gene transfer; brain; gene therapy; ischemia; neurogenesis; stem cell; stroke; vector

Document Type: Research Article

Publication date: 01 February 2011

More about this publication?
  • Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

    Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content